AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to ...

As for Chia Tai Feng Hai, the company is owned by parent company Sino Biopharmaceutical, a large China pharma based in Hong ...

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of ...

Roche has waved goodbye to an inflammation drug from Kiniksa Pharmaceuticals—as well as the $100 million that the pharma paid for the therapy—as part of a ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

The next major drugmaker interested in what Repertoire has to offer is Eli Lilly, which has thrown down $85 million upfront and floated up to $1.84 billion more in biobucks to collaborate on potential ...

Full-year sales for Roche’s diagnostics division were up by just 2% as the Big Pharma deals with ongoing challenges in China.  | Full-year sales for Roche’s diagnostics division were up by just 2% as ...

Sanofi is tight-lipped about the future of its underwhelming pact with Denali Therapeutics after the French pharma scrapped what appeared to be the final RIPK1 inhibitor from the deal. | Sanofi is ...

Like many life sciences outfits undergoing a restructuring, Charles River Laboratories is balancing layoffs and a business ...

Vertex is running a phase 2 trial of inaxaplin in APOL1-mediated kidney diseases, including some forms of FSGS. The phase 3 ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...

CalciMedica’s stock nosedived after the biotech abandoned a phase 2 study of its calcium release-activated calcium (CRAC) ...